Navigation Links
Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
Date:5/14/2009

ells and platelets.

Eight of the 10 patients had high-risk genomic features and no dose-limiting toxicities or serious adverse events had occurred. Mild (grade 1-2) infusion toxicity was observed in three patients. Beginning with the 0.3 mg/kg dose, all eight patients demonstrated evidence of biological activity including high-risk patients. Two patients had partial clearing of leukemia cutis, and the other six had 27% to 94% reduction in peripheral lymphocyte count. One patient had an increase in hemoglobin of 40% and a reduction in lymph nodes of 36%. Two patients had a significant increase in platelet count.

TRU-016 is a humanized SMIP protein therapeutic that targets the CD37 antigen and has shown potent anti-tumor activity in pre-clinical studies. Trubion initiated a Phase 1/2 clinical trial of TRU-016 in March 2008. The open-label clinical trial has two components: a Phase 1 dose escalation study designed to evaluate the safety, tolerability and pharmacokinetics of TRU-016, and a Phase 2 expansion cohort designed to further evaluate safety and estimate clinical activity of TRU-016 in patients with previously treated CLL or small lymphocytic lymphoma (SLL).

Abstract 8571 (May 30, 2009): Evaluation of the Effect of TRU-016 in Combination With Other Therapeutic Drugs in Models of Non-Hodgkin's Lymphoma

In addition, Trubion will also present at the 2009 ASCO Annual Meeting preclinical data evaluating TRU-016 interactions with the established therapeutics rituximab, doxorubicin, rapamycin, and bendamustine. Drugs were tested alone or in combination with TRU-016 for anti-proliferative effects on cell lines in vitro and on tumors in vivo.

Combination index analyses revealed that TRU-016 is synergistic with rituximab, bendamustine, or rapamycin and additive with doxorubicin in killing NHL cells in vitro. In vivo results show that treatment with the combination of TRU-016
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
2. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
3. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
4. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
5. Trubion Announces Presentations at Upcoming Investor Conferences
6. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
7. Trubion Announces Presentations at Upcoming Investor Conferences
8. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
9. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
10. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Athena San Diego, an organization that accelerates ... San Diego’s technology and life science sectors, will announce ... their Gala on April 30, 2015 from 5-9pm at ... http://athenasd.org/events/ , The Pinnacle Awards recognize individuals and ... of fostering networking, risk taking and diversity of thought, ...
(Date:4/23/2015)... April 23, 2015 /CNW/ - A new and innovative ... from North America,s largest ... won Silver in the "Sustainability, service" category of ... Brandcheck "Competitor Comparison" is a service that scores ... and Global peers. This benchmarking process shows clients ...
(Date:4/23/2015)... D.C. (PRWEB) April 23, 2015 ... D.C. region on April 4-17 as part of ... marks the fourth group of biotechnology startups to ... of Nizhny Novgorod (UNN) and the University of ... deepen ties between their respective universities in the ...
(Date:4/23/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology and medical device industries, with ... the United States , today announced that ... of 2015 after the New York Stock Exchange closes ... morning, May 14, 2015 Shanghai time). The earnings release ...
Breaking Biology Technology:Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... pampered pushovers. O,Reilly et al. report that certain stem ... to control their division and differentiation., Some stem cells ... a structure called the niche. The niche not only ... whether they reproduce and specialize. The standard view is ...
... SAN DIEGO, Aug. 25 Amylin Pharmaceuticals,Inc. (Nasdaq: ... LLY ) will Web cast a,conference call on ... to,discuss the recent FDA advisory on BYETTA(R) (exenatide) injection. ... Amylin,s President and,Chief Executive Officer and Orville G. Kolterman, ...
... Experts Dodson and Tannenbaum Join as Chief ... Executive Officer, Chief Financial Officer, SUNNYVALE, Calif., Aug. ... appointed medical device industry experts,Scott Dodson as President and Chief ... Chief Financial Officer (CFO). Both,executives will assume key roles with ...
Cached Biology Technology:Amylin and Lilly Set Date and Time for Conference Call 2Avantis Medical Systems, Inc. Announces Key Leadership Appointments 2
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
(Date:3/20/2015)... March 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... one of the products featured in 2015 "I Want ... 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 International ...
(Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... The Quaking gene, first described as a mutation in ... tumor formation and protect humans from cancer. , ... the University of Wisconsin has shown that the Quaking ... a protein associated with GLI1, a cancer-causing oncogene highly ...
... Research Center at Oregon Health & Science University (OHSU) ... how stem cells become various kinds of brain cells. ... Parkinson's disease, brain and spinal cord injury, and other ... lost or damaged brain cells. The research is published ...
... olive oil, which have antioxidant, anti-inflammatory and anti-clotting ... the so-called Mediterranean Diet, according to a new ... the Journal of the American College of Cardiology. ... of the Mediterranean diet on cardiovascular disease and ...
Cached Biology News:Researchers discover new form of cancer gene regulation 2Researchers discover new form of cancer gene regulation 3OHSU discovery sheds light into how stem cells become brain cells 2Phenolic compounds may explain Mediterranean diet benefits 2Phenolic compounds may explain Mediterranean diet benefits 3
AC input: 50-60 Hz230 V...
AC input: 50-60 Hz 115-120 V...
... reagent is formulated specifically for Alkaline Phosphatase ... levels of activity for both the enzyme ... final dilution. This product has been ... the customer a longer shelf life, resistance ...
... The SDSaway reagent is a valuable tool ... The presence of SDS in biological ... tightly bound SDS-protein complex, inhibits enzymatic activity ... presents as a contaminant in mass spectrometry ...
Biology Products: